Comment
doi: 10.1016/S1470-2045(14)70386-9.
Epub 2014 Aug 27.
What new therapeutic targets exist for EGFR-mutant NSCLC?
Affiliations
- PMID: 25175098
- DOI: 10.1016/S1470-2045(14)70386-9
Item in Clipboard
Comment
What new therapeutic targets exist for EGFR-mutant NSCLC?
Lancet Oncol.
2014 Oct.
No abstract available
Comment on
-
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27. Lancet Oncol. 2014. PMID: 25175099 Clinical Trial.
Similar articles
-
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.Rev Recent Clin Trials. 2017;12(1):51-58. doi: 10.2174/1574887111666160916130423. Rev Recent Clin Trials. 2017. PMID: 27633965 Clinical Trial.
-
New therapy targets resistant non-small-cell lung cancers.J Natl Cancer Inst. 2014 Nov 23;106(11):dju393. doi: 10.1093/jnci/dju393. Print 2014 Nov. J Natl Cancer Inst. 2014. PMID: 25421346 No abstract available.
-
Optimising therapy for EGFR-addicted NSCLC: just the start.Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285167 No abstract available.
-
[Erlotinib in the treatment of non-small cell lung cancer].Magy Onkol. 2006;50(3):237-41. Epub 2006 Nov 12. Magy Onkol. 2006. PMID: 17099784 Review. Hungarian.
-
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw279. J Natl Cancer Inst. 2017. PMID: 28376144 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
